Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLWAVE-010: Nemtabrutinib + Venetoclax vs Venetoclax + Rituximab in R/R CLL/SLL
NCT05947851Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2023
- Primary completion
- Jun 2032
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of nemtabrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Merck & Co.. Started Aug 2023; status: recruiting.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05947851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947851.